Search
nintedanib; vargatef (Ofev, BIBF-1120)
Indications:
- idiopathic pulmonary fibrosis*
- progressive interstitial lung disease [5]
* on list of drugs to avoid; no survival benefit [3]
* FDA-approved [4]
* slows progression of disease on pulmonary function tests [4]
* does not elevate patients' perceived quality of life,[4]
Contraindications:
- liver failure
- pregnancy
Dosage:
- 150 mg PO BID
Adverse effects:
- diarrhea (common)
- nausea, vomiting
- abdominal pain
- hepatotoxicity [3]
- abnormal liver function tests
- anorexia
- headache
- weight loss
- hypertension
- risk of thromboembolism [3]
Mechanism of action:
- tyrosine kinase inhibitor
- may attenuate lung-function decline & acute exacerbations in patients with idiopathic pulmonary fibrosis [1]
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
small inhibitory antineoplastic agent (ib drug)
antineoplastic tyrosine kinase inhibitor
Database Correlations
PUBCHEM correlations
References
- Richeldi L et al
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary
Fibrosis.
N Engl J Med. May 18, 2014
PMID: 24836310
http://www.nejm.org/doi/full/10.1056/NEJMoa1402584
- FDA News Release. October 15, 2014
FDA approves Ofev to treat idiopathic pulmonary fibrosis
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418994.htm
- Therapeutics Letter #108. Therapeutics Initiative
Drugs to Avoid.
http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
- Dempsey TM, Sangaralingham LR, Yao Xet al.
Clinical effectiveness of antifibrotic medications for idiopathic
pulmonary fibrosis.
Am J Respir Crit Care Med 2019 Jul 15; 200:168
PMID: 31150266
https://www.atsjournals.org/doi/10.1164/rccm.201902-0456OC
- FDA News Release. March 9, 2020
FDA Approves First Treatment for Group of Progressive Interstitial
Lung Diseases.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-group-progressive-interstitial-lung-diseases